Please login to the form below

Not currently logged in
Email:
Password:

bococizumab

This page shows the latest bococizumab news and features for those working in and with pharma, biotech and healthcare.

Amgen wins block on sales of Sanofi/Regeneron's Praluent

Amgen wins block on sales of Sanofi/Regeneron's Praluent

A potential third entrant - Pfizer's bococizumab - was dropped from development last year.

Latest news

  • Amgen's Repatha unclogs blocked arteries, says study Amgen's Repatha unclogs blocked arteries, says study

    The difficulties experienced by the first two PCSK9 inhibitors in the market played a role in Pfizer deciding to drop its own candidate bococizumab, which was set to become the third

  • Pfizer dropping bococizumab casts shadow over PCSK9 class Pfizer dropping bococizumab casts shadow over PCSK9 class

    Pfizer dropping bococizumab casts shadow over PCSK9 class. US payer resistance and diminishing efficacy prompt decision on would-be blockbuster. ... Pfizer has decided it will no longer try to bring its cholesterol-lowering antibody bococizumab to market,

  • Pfizer's PCSK9 inhibitor clears another phase III trial Pfizer's PCSK9 inhibitor clears another phase III trial

    Pfizer's PCSK9 inhibitor clears another phase III trial. Bococizumab will compete with Praluent and Repatha if it reaches the market. ... Pfizer has reported positive phase III trial results with its cholesterol-lowering candidate bococizumab, setting up

  • Amgen starts shipping Corlaner in US Amgen starts shipping Corlaner in US

    Repatha and other PCSK9 inhibitors such as Sanofi/Regeneron's alirocumab and Pfizer's bococizumab are considered future blockbusters thanks to their ability to help more patients meet cholesterol targets.

  • Monthly dosing effective for Sanofi's alirocumab Monthly dosing effective for Sanofi's alirocumab

    A third PCSK9 inhibitor - Pfizer's bococizumab (RN316) - has also reported results from phase III trials but is expected to lag a little behind the leaders in terms of market share.

More from news
Approximately 3 fully matching, plus 12 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Swordfish Advertising

At Swordfish Advertising, we believe building an effective brand shouldn't be stressful. Don't get us wrong; it takes blood, sweat...

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics